A year after the US Food & Drug Administration approved brensocatib (Brinsupri) as the first disease-modifying therapy for non-cystic fibrosis bronchiectasis, pulmonologists are refining which patients benefit most while reporting a tolerability profile that has not deterred uptake.

The FDA approved brensocatib for non-cystic fibrosis bronchiectasis on August 12, 2025. The decision was based on the phase 3 ASPEN trial, which enrolled > 1700 patients and showed both the 10 mg and 25 mg doses of brensocatib reduced annualized exacerbation rates by 20% compared with placebo. The 25 mg dose also showed lung function decline over 12 months.¹

bensocatib Patient Selection Evolves 1 Year After FDA Approval

Bensocatib Patient Selection Evolves 1 Year After FDA Approval

Mark L. Metersky, MD, FCCP, FACP, professor of medicine and director of the Center for Bronchiectasis Care at UConn Health, has prescribed brensocatib since its approval and shared his approach to patient selection and tolerability in an interview with 

"Bronchiectasis is quite heterogeneous, so it's likely not every patient will benefit," Metersky said. "For me, what I'm doing is using it in patients who have frequent exacerbations."

Brensocatib Patient Selection and ASPEN Trial Data

The ASPEN trial randomized patients with non-cystic fibrosis bronchiectasis to 10 mg brensocatib, 25 mg brensocatib, or placebo for 52 weeks across international sites. Both doses met the primary endpoint of a reduced annualized exacerbation rate compared with placebo, and the 25 mg dose additionally slowed the rate of forced expiratory volume in 1 second (FEV1) decline.¹

Metersky said patients with a high daily symptom burden, such as frequent cough with copious purulent sputum despite an absence of frequent exacerbations, may also derive benefit based on the drug's mechanism of action and the pattern of trial results. He added patients with rapidly declining lung function are additional potential candidates, given the 25 mg dose's demonstrated effect on FEV1 decline, though data specific to this subgroup remain unavailable.

Brensocatib Safety Profile and Patient Tolerability

Brensocatib (Brinsupri) is approved by the FDA as a disease-modifying therapy for non-cystic fibrosis bronchiectasis in patients 12 years and older, based on results from the phase 3 ASPEN trial.

Brensocatib is an oral, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1), an enzyme responsible for activating neutrophil serine proteases implicated in bronchiectasis airway inflammation.

Which bronchiectasis patients are most likely to benefit from brensocatib? 

Metersky prioritizes patients with frequent exacerbations, the population studied in ASPEN, and considers patients with a high daily symptom burden or rapidly declining lung function additional potential candidates, though these groups were not directly studied in the trial.

The most common adverse events in ASPEN were consistent with the safety profile observed in earlier studies, and the phase 3 trial did not show a significant signal for increased periodontal disease risk with brensocatib.¹ Metersky said the drug's distinctive tolerability profile, including hyperkeratosis and periodontal changes, has not deterred patients from starting or continuing therapy in his practice.

He recalled one patient who asked if her teeth would fall out before starting treatment.

"That's not been an issue patients fear," said Metersky. "In truth, we didn't really see a significant signal for increased risk of periodontal disease in the phase 3 study."

He advises patients to brush twice daily, floss, and see their dentist regularly, noting any periodontal changes would likely develop slowly and be caught early. Metersky said he has also observed skin thickening and sloughing, most often behind the knees, elbows, feet, and hands, in one patient, but described the finding as uncommon in his experience.

The 1-year mark followed the American College of Chest Physicians' first North American clinical practice guideline for adult bronchiectasis, published in 2026, which includes long-term brensocatib among 13 conditional recommendations for patients with frequent exacerbations.³ Even with an approved therapy and dedicated guideline, unmet needs such as chronic cough, sputum burden, and disease progression persist across the bronchiectasis population.⁴

Watch the accompanying dynamic feature here: 

One Year Later: How Brensocatib Has Changed Bronchiectasis Care

Chalmers JD, et al. Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. 

FDA approves first bronchiectasis therapy, brensocatib, for ages 12 and up. HCPLive. Published August 12, 2025. Accessed August 21, 2026. 

https://www.hcplive.com/view/fda-approves-first-bronchiectasis-therapy-brensocatib-12-up

CHEST guideline 2026: 13 recommendations for non-CF bronchiectasis. HCPLive. Accessed August 21, 2026. 

https://www.hcplive.com/view/chest-guideline-2026-13-recommendations-bronchiectasis

Metersky M, Basavaraj A, Johnson V. One year later: how brensocatib has changed bronchiectasis care. HCPLive. Accessed August 21, 2026. 

https://www.hcplive.com/view/one-year-later-how-brensocatib-has-changed-bronchiectasis-care

Videos

One year after FDA approval, Mark Metersky, MD, discusses which bronchiectasis patients benefit most from brensocatib and its safety profile.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Pulmonary Fibrosis

Brensocatib Patient Selection Evolves 1 Year After FDA Approval

Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.Each week, we highlight 5 key developments or headlines from healthcare that you need to know — whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine.

This week's top stories include the US Food and Drug Administration (FDA) approval of an autoinjector formulation of lerodalcibep-liga (Lerochol) and an updated indication statement for MACE reduction, topline phase 3 data for avexitide in adults with post-bariatric 

 following Roux-en-Y gastric bypass surgery, the FDA’s acceptance of a New Drug Application (NDA) for ecopipam (EBS-101) in pediatric Tourette syndrome, the accelerated approval of pariglasgene brecaparvovec-opnr (Genglycos) for glycogen storage disease type Ia (GSD1a), and the FDA’s Fast Track designation of LTI-03 for 

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here's your quick dive into the top stories for the week of August 16, 2026 — let's jump in!

Lerodalcibep Autoinjector Receives FDA Approval for Hypercholesterolemia

On August 17, 2026, the FDA approved an autoinjector formulation of LIB Therapeutics’ lerodalcibep-liga (Lerochol), a third-generation PCSK9 inhibitor. The single-use device delivers the existing once-monthly, 300 mg/1.2 mL dose via a pressure-activated, single-motion injection completed in seconds.

The Agency also approved an updated indication statement for lerodalcibep-liga reflecting the established reduction in major adverse cardiovascular events (MACE) achieved through LDL-C lowering in adults with hypercholesterolemia treated with statins or with monoclonal antibody PCSK9 inhibitors added to statin therapy.

Avexitide Reduces Hypoglycemic Events in Phase 3 LUCIDITY Trial for PBH

On August 18, 2026, Amylyx Pharmaceuticals announced positive topline results from the phase 3 LUCIDITY trial evaluating avexitide in adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass (RYGB) surgery.The trial met its primary endpoint as agreed with the FDA, with the investigational glucagon-like peptide-1 (GLP-1) receptor antagonist reducing the composite rate of Level 2 and Level 3 hypoglycemic events by 55% compared with placebo (

 = .000003). LUCIDITY also met all secondary endpoints.

FDA Accepts NDA for Ecopipam in Pediatric Tourette Syndrome

On August 19, 2026, the FDA accepted Teva Pharmaceuticals' NDA for ecopipam (EBS-101), a first-in-class selective D1 receptor antagonist, and granted Priority Review for the treatment of pediatric patients with Tourette syndrome, with a target action date late in the first quarter of 2027.

"If approved, ecopipam would be the first new therapy for Tourette syndrome in more than 10 years and the first novel mechanism of action in more than 50 years, offering patients and families a long-awaited new treatment option,” Eric Hughes, MD, PhD, executive vice president, Global R&D and chief medical officer, at Teva, said in a statement.

FDA Approves Gene Therapy for Glycogen Storage Disease Type 1a

On August 20, 2026, the FDA granted accelerated approval to pariglasgene brecaparvovec-opnr (Genglycos), a one-time AAV8 gene therapy, to reduce daily cornstarch intake as an adjunct to nutritional management in patients 8 years and older with GSD1a, making it the first approved treatment for the condition.

FDA Fast Tracks LTI-03 for Idiopathic Pulmonary Fibrosis

On August 20, 2026, the FDA granted Fast Track designation to LTI-03, an inhaled peptide therapy from Rein Therapeutics, for IPF. The decision follows a prior Orphan Drug designation already granted to LTI-03 for IPF, whose Caveolin-1-derived mechanism sets it apart from existing antifibrotics by targeting alveolar epithelial repair alongside fibrotic signaling.

Articles

Multiple FDA actions and late-stage readouts spanned cardiometabolic, neurologic, rare genetic, and pulmonary disease programs. Lerodalcibep-liga gained an autoinjector option for monthly PCSK9 inhibition and an updated MACE-reduction indication tied to LDL-C lowering. Avexitide achieved a highly significant 55% reduction in clinically meaningful hypoglycemic events in phase 3 post–Roux-en-Y post-bariatric hypoglycemia. Ecopipam’s pediatric Tourette NDA was accepted with Priority Review. AAV8 gene therapy pariglasgene brecaparvovec-opnr received accelerated approval for GSD1a. LTI-03 secured Fast Track for IPF.

Stay updated with the latest healthcare breakthroughs, including a new lerodalcibep FDA approval and phase 3 avexitide data in post-bariatric hypoglycemia.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


The HCPFive: Top News for Healthcare Providers from the Week of 08/16

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Daniel Taylor-Sweet, PhD | Image Credit: LinkedIn

 screening strategy has identified a substantial proportion of patients living with diabetes with unrecognized symptomatic HF, highlighting the need for further adoption of similar screening techniques.

HF is a frequent complication in patients with diabetes. Risk is elevated even after controlling risk factors like hypertension, hypercholesterolemia, hyperglycemia, and albuminuria. Additionally, the increasing incidence of 

 is expected to increase the incidence of HF. However, guidelines for HF treatment do not consistently include biomarker-based screening, and it is rarely performed in clinical practice.

“To address this knowledge gap, we conducted a randomized controlled trial evaluating the diagnostic yield of a systematic natriuretic peptide-guided screening strategy to detect unrecognized symptomatic HF in adults with diabetes and additional risk factors for HF,” Daniel Taylor-Sweet, PhD, clinical fellow at NHS Golden Jubilee and research fellow at the University of Glasgow, and colleagues wrote.

TARTAN-HF was a prospective, multicenter, unblinded, randomized controlled trial, one of several in the broader SYMPHONY program. This program aimed to examine the potential benefits of HF screening in a variety of populations. TARTAN-HF enrolled patients ≥40 years of age with an established diagnosis of 

 or T2D and ≥1 additional risk factor for HF. These risk factors included coronary artery disease, previous ischemic or embolic stroke, peripheral artery disease, or chronic obstructive pulmonary disease, among other factors.

Prior to randomization, medical and drug history were recorded, and patients were invited to complete the Kansas City Cardiomyopathy Questionnaire (KCC-12) and the EuroQol 5-Dimension 3-Level questionnaire. Eligible patients were then randomly assigned in a 1:1 ratio to either screening or usual care for HF, after which they were invited to an in-person study visit during which investigators measured NT-proBNP, sampled peripheral venous blood for hematology and biochemistry, sampled urine for urinary albumin-to-creatinine ratio, and a 12-lead electrocardiograph.

The trial’s primary endpoint was a diagnosis of HF at 6 months after randomization. This was defined as the presence of each of the following 3 criteria: signs and/or symptoms of HF, an elevated NT-proBNP concentration ≥125 pg/mL, and ≥1 echocardiographic structural or functional abnormality consistent with adverse cardiac remodeling or elevated filling pressures. These diagnoses were classified according to ejection fraction phenotype.

A total of 706 patients were randomized between January 2023 and May 2025, with 354 assigned to screening and 352 to usual care. Median age was 71 years, and 90% of patients had T2D. Median duration of diabetes was 12.5 years. 72% of patients had their diabetes managed in primary care, while the remainder were attending a secondary care diabetes clinic. The most common risk factors were chronic kidney disease (57%) and coronary artery disease (39%).

Among the patients assigned to screening, an HF diagnosis was ultimately made in 87 (24.6%). A diagnosis of HF with reduced ejection fraction (HFrEF) was made in 3 patients, HF with mildly reduced ejection fraction (HFmrEF) was made in 3 patients, and HF with preserved ejection fraction (HFpEF) in 81 patients (23%). No further diagnoses were made in the 6 months following randomization outside of the screening process. However, the usual care group only saw 2 diagnoses (odds ratio [OR], 58; 95% CI, 14-236; 

Ultimately, Taylor-Sweet and colleagues concluded that NT-proBNP-based screening is an effective method for improving HF diagnosis among patients who would otherwise have gone unrecognized. The team encourages further adoption of this and similar screening strategies to combat HF.

“The high diagnostic yield of the proposed screening strategy strengthens the case for the consideration of the implementation of natriuretic peptide-based screening for undiagnosed symptomatic HF in high-risk people with diabetes,” Taylor-Sweet and colleagues wrote.

Taylor-Sweet, D, Petrie, M, McKinley, G. et al. Targeted Assessment in High-Risk Patients With Diabetes to Identify Undiagnosed Heart Failure (TARTAN-HF). 

https://doi.org/10.1016/j.jacc.2026.06.042

McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. 

https://academic.oup.com/eurheartj/article/42/36/3599/6358045

Systematic natriuretic peptide–guided screening using NT-proBNP in high-risk adults with diabetes uncovered a large burden of previously unrecognized symptomatic heart failure, predominantly HFpEF. In a prospective, multicenter randomized trial of older patients with long-standing diabetes and added cardiovascular comorbidity, screening markedly increased 6‑month HF diagnoses versus usual care, which detected very few cases. Diagnostic criteria required symptoms/signs, NT-proBNP ≥125 pg/mL, and supportive echocardiographic abnormalities. Findings support broader implementation of biomarker-based HF screening in diabetology care pathways.

A recent study has shown that a significantly greater proportion of patients with HF were correctly identified when testing NT-proBNP levels.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Type 1 Diabetes

Type 2 Diabetes

NT-proBNP Sampling May Improve Heart Failure Screening in Patients With Diabetes

Leadership in medicine rarely comes with a manual for what happens outside the clinic. In this segment of the 

, Tiffany Mayo, MD, associate professor at the University of Alabama at Birmingham who will soon join UT Southwestern in Dallas, joined host Mona Shahriari, MD, associate clinical professor of 

 at Yale University, to discuss 2 of those unspoken challenges: protecting personal boundaries and navigating what it means to represent more than yourself.

How Women of Color in Medicine Navigate Representation Pressure

Shahriari and Mayo discussed how expectations around availability have shifted in medical education, with mentees increasingly expecting immediate responses regardless of personal or professional demands on a mentor's time. Mayo said she has learned to communicate response-time expectations clearly to trainees, recognizing that other people's sense of urgency does not have to become her own. She said failing to set these boundaries can compromise a mentor's ability to meet their own professional goals while supporting others.

Does Representation Pressure Feel Different for Women of Color in Medicine?

Shahriari asked Mayo whether pressure to conform feels heightened for women of color, given concerns about losing standing in professional spaces. Mayo said that pressure is real, since women of color in medicine often feel they represent broader communities and organizations rather than only themselves. She said she has come to view her presence in leadership spaces as an opportunity to contribute a distinct perspective rather than default to agreement, citing dermatologist Steve Daveluy, MD, whose own textured hair experience shapes how he approaches patients with similarly textured hair, as an example of how lived experience adds irreplaceable value.

How Does Authenticity Intersect With Professional Expectations?

Mayo also reflected on adapting her appearance, including straightening her hair for residency interviews, to align with perceptions of professionalism at the time. She said such adjustments do not necessarily compromise authenticity, but reflect cultural norms placed on those outside a profession's dominant group. Mayo said that while some adaptation may occur, staying true to one's core values and voice once seated at the table remains non-negotiable.

Editor’s note: Neither speaker had any relevant disclosures of note. This episode was summarized with the help of AI tools.

Want to join The Medical Sisterhood community? Click here to join our LinkedIn Group!

Shahriari M, Mayo T. The Medical Sisterhood: The Pressure of Representation, With Tiffany Mayo, MD. HCPLive. August 13, 2026. Accessed August 21, 2026. 

https://www.hcplive.com/view/medical-sisterhood-pressure-representation-tiffany-mayo-md

This segment of The Medical Sisterhood podcast highlights setting boundaries in mentorship and the pressure of representation for women of color in medicine.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Nearly 80% of young adults in a new study were classified in an early or intermediate stage of cardiovascular-kidney-metabolic (CKM) health, with excess adiposity emerging as the leading driver. The findings, published in Circulation: Population Health and Outcomes, suggest the seeds of atherosclerosis may be sown far earlier than previously appreciated.

"Even though heart attacks and strokes most often affect us in our 40s, 50s, 60s, actually the thing that is leading up to those heart attacks really starts to get rolling in our 20s," Donald Lloyd-Jones, MD, MS, said in an interview with HCPLive.

4 Out of 5 Young Adults Show Early Cardiovascular-Kidney-Metabolic Risk

Lloyd-Jones is an American Heart Association volunteer, a cardiologist at Boston Medical Center, professor of medicine at Boston University's Chobanian & Avedisian School of Medicine, director of the Framingham Center for Population and Prevention Science, and principal investigator of the Framingham Heart Study.

Why Young Adulthood Is a Blind Spot in Cardiovascular Prevention

Findings from prior research suggest traditional risk factors, including elevated cholesterol, elevated blood pressure, diabetes, and smoking, are associated with arterial damage in older adults. That damage, measurable by carotid ultrasound, is an indicator of greater risk for myocardial infarction and stroke. Previous research also shows levels of these risk factors in childhood, even within the normal range, are associated with greater plaque buildup later in life.

To address this gap in research, few studies have quantified this kind of arterial injury specifically in young adults, a period Lloyd-Jones and colleagues believe is critical to understanding who is on a fast track toward cardiovascular disease.

"Young adulthood, we think, is a time when atherosclerosis or plaques are really starting to get going," Lloyd-Jones said.

The CKM construct itself reflects this cardiovascular-kidney interconnection: stage 2 CKM is defined by the presence of either metabolic risk factors or kidney risk factors, and stage 3 by subclinical cardiovascular disease or advanced kidney disease, meaning kidney function is embedded in the staging system alongside traditional cardiometabolic measures rather than considered separately.

Investigators analyzed data from 1283 participants (mean age, 22.9 years; 54.4% women) in the Future of Families–Cardiovascular Health Among Young Adults (FF-CHAYA) study, an ancillary study of the Future of Families and Child Well-Being Study that Lloyd-Jones helps lead. The cohort included oversampling of participants from disadvantaged backgrounds, including unmarried mothers and those living below the poverty line.

Participants underwent carotid ultrasonography to assess early arterial injury and were classified using the American Heart Association's CKM staging construct, which ranges from stage 0 (no risk factors) to stage 4 (clinical cardiovascular disease); this analysis excluded stage 4, given its focus on primary prevention. Cardiovascular health was also quantified using Life's Essential 8 (LE8) scores, a composite of 8 metrics including diet, physical activity, sleep, nicotine exposure, body mass index, blood glycemia, blood lipids, and blood pressure.

Only 1 in 5 Young Adults Had Optimal Cardiovascular Health

Investigators found 20.7% of participants were classified as stage 0 CKM, with no CKM risk factors. The remaining 79.3% were classified in stage 1 or higher: 40.2% in stage 1 (excess or dysfunctional adiposity), 36.2% in stage 2 (metabolic or kidney risk factors), and 2.8% in stage 3 (subclinical cardiovascular disease or advanced kidney disease).

"Only about 20% of these young adults...seemed to be in kind of optimal health," Lloyd-Jones said. "Eighty percent of them were in stage 1 or higher cardiovascular kidney metabolic health."

More advanced CKM stage was associated with significantly lower LE8 scores, from 77.6 in stage 0 to 70.0 in stage 1, 63.8 in stage 2, and 64.4 in stage 3 (P < .001). Notably, this decline was driven by physiological measures, including body mass index, blood lipids, blood pressure, and glycemia, rather than self-reported health behaviors; scores for diet, physical activity, sleep, and nicotine exposure did not differ significantly across CKM stages.

Kidney-related measures also tracked with CKM stage. Mean estimated glomerular filtration rate declined across stages, from 117.7 mL/min/1.73 m² in stage 0 to 111.5 mL/min/1.73 m² in stage 3, and mean creatinine was highest in stage 3 (1.4 mg/dL) relative to earlier stages (0.8 mg/dL). Investigators noted that while variation in glycemia and kidney function was less pronounced than variation in adiposity, blood pressure, and lipids in this young cohort, early kidney involvement was still detectable well before clinical disease.

"That early weight gain is really a key driver of the whole process that leads people to developing either heart or kidney problems over lifetimes," Lloyd-Jones said.

Arterial Injury Was Already Detectable in Participants' Early 20s

More advanced CKM stage was also associated with significantly greater carotid intima-medial thickness (cIMT), an early marker of atherosclerosis. Compared with stage 0, mean-maximum cIMT was 0.014 mm greater in stage 1 (95% CI, 0.005-0.020), 0.020 mm greater in stage 2 (95% CI, 0.017-0.035), and 0.100 mm greater in stage 3 (95% CI, 0.085-0.128).

Although these differences are small in absolute terms, investigators noted prior research has linked even modest cIMT differences to significantly greater risk of myocardial infarction and stroke in older adults, associations they suggest may be amplified in a younger population.

What These Findings Mean for Physicians Seeing Patients in Their 20s

"In your early 20s is actually a really really important time to be connected with the healthcare system, to have a healthcare practitioner, to make plans," Lloyd-Jones said.

Lloyd-Jones noted that in most cases, risk factors identified in a patient's 20s can be addressed through lifestyle change alone, including improved eating patterns and more regular physical activity, potentially restoring health rather than simply preserving it. He said medication is rarely necessary in this age group unless risk factors are already significantly elevated, underscoring the importance of knowing key numbers, including cholesterol, blood pressure, and blood glucose trends, earlier rather than later.

"Things may already be getting started that could affect them either shortening their lifespan or really degrading their health for the long term," Lloyd-Jones said.

Krishnan V, Ning H, Notterman DA, et al. Association between cardiovascular-kidney-metabolic health and early arterial injury in young adults in the United States: the Future of Families–Cardiovascular Health Among Young Adults Study. 

. 2026;19:e013042. doi:10.1161/CIRCOUTCOMES.125.013042

Ndumele CE, Rangaswami J, Chow SL, et al; American Heart Association. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. 

. 2023;148:1606-1635. doi:10.1161/CIR.0000000000001184

Carotid ultrasound data reveal early arterial injury even at earlier CKM stages, says Donald Lloyd-Jones, MD, MS

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Manish Wadhwa, MD, is a cardiologist and electrophysiologist with San Diego Arrhythmia Associates and the chief executive officer of SummaCor.

Manish Wadhwa, MD, discusses Implicity’s newest algorithm to improve the accuracy of implantable cardiac monitors in identifying arrhythmic episodes.

Arrhythmia

FDA News

FDA-Cleared, AI-Assisted ECG Analyzer Algorithm Reduces False Positives in ICMs

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Pamufetinib 50 mg and 100 mg did not slow FVC decline versus continued nintedanib or pirfenidone in progressive fibrosing ILD, a phase 2b trial found.

Pamufetinib Fails to Slow FVC Decline in Progressive Fibrosing ILD

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD

Melinda Gooderham, MD, is a dermatologist and the medical director at the SKiN Centre for Dermatology.

This Q&A interview continues Gooderham's discussion of new upadacitinib treatment data on patients living with severe alopecia areata.

Alopecia

Q&A: Upadacitinib Drives Eyebrow, Eyelash Regrowth with Consistent Safety

Andrew Mastro, MS, PA-C, closes out this stretch of the conversation by asking Alexa Hetzel, MS, PA-C, to look three to five years ahead and describe how she expects the plaque psoriasis treatment paradigm to evolve.

The Future of Plaque Psoriasis Treatment Over the Next 3 to 5 Years

Andrew Mastro, MS, PA-C, widens the lens and asks Alexa Hetzel, MS, PA-C, where icotrokinra sits within the broader plaque psoriasis landscape, including whether route of administration itself shapes patient preference.

Positioning Icotrokinra as First-Line Therapy for Plaque Psoriasis

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

PAH specialists discuss upfront combination therapy and the disconnect between guidelines and community practice.

PAH in Community Practice: Algorithms and Access

Genetic variants tied to CAR T toxicity and expansion could guide how researchers screen healthy donors for allogeneic CAR T products.

Hematology

Selecting Donor T Cells for CAR T Therapy, With Mark B. Leick, MD

This Q&A interview highlights key new data from the UP-AA1 and UP-AA2 trials on upadacitinib for severe alopecia areata.

Q&A: Upadacitinib Meets Primary Endpoint in Severe Alopecia Areata Trials

Nathaniel Lebowitz, MD, is an attending cardiologist at the Hackensack University School of Medicine and an assistant professor of internal medicine at the Hackensack Meridian School of Medicine.

Lp(a) is one of the biggest contributors to cardiovascular disease, but recent studies have shown that awareness of and testing for the condition is subpar nationwide.

Latest News

Brensocatib Patient Selection Evolves 1 Year After FDA Approval

The HCPFive: Top News for Healthcare Providers from the Week of 08/16

NT-proBNP Sampling May Improve Heart Failure Screening in Patients With Diabetes

How Women of Color in Medicine Navigate Representation Pressure

4 Out of 5 Young Adults Show Early Cardiovascular-Kidney-Metabolic Risk